HNGE

Analyst Note: Hinge Health, Inc. (HNGE)

Date: 2026-06-20 Event Date: 2026-06-20

1. Structural Readiness

• Setup State: Watchlist
• Conservative Entry: Not yet defined (awaiting breakout confirmation)
• Current Price: $69.42
• Extension: Not applicable (price is within the consolidation range)
• Breakout Level: Not yet defined (requires price to close above the upper boundary of the forming coil)
• ATR Context: Current ATR is 4.7% (High). This indicates elevated volatility, which is consistent with the "High" bucket (4–6%) often seen in growth leaders approaching inflection points.

2. Thesis Layer

As of 2026-06-20, HNGE is classified as a TACTICAL, setup-led name. There is no named secular thesis attached to this specific setup at this date. The investment case must be judged strictly on the quality of the technical setup (the forming coil) and the underlying business fundamentals provided in the evidence block. No macro or thematic thesis should be invented to support the trade; the conviction rests on the convergence of strong operational execution and a technical structure that is primed for a potential breakout.

3. Business Overview

Hinge Health operates as a digital musculoskeletal (MSK) care platform, delivering personalized care through AI-powered motion tracking and proprietary electrical nerve stimulation wearables, monitored by a team of licensed physical therapists and physicians.

• Business Model: The company serves primarily self-insured employers, health plans (fully-insured and Medicare Advantage), and federal insurance plans. Revenue is generated through contracts with these payers, leveraging a high retention rate and a growing client base.
• Scale & Growth (as of Q1 2026):
• Revenue: Generated $182 million in Q1 2026, representing 47% year-over-year growth compared to $124 million in Q1 2025.
• Billings: Last 12 months calculated billings reached $770 million, a 52% increase from $507 million in the prior year period.
• Client Base: Expanded to 2,849 clients as of March 31, 2026, up from 2,311 clients a year prior.
• Retention: The 12-month client retention rate was 97% as of December 31, 2025.
• Product Expansion: In 2025, the company launched "HingeSelect," a high-performance in-person provider network, allowing for end-to-end MSK care. While management expects revenue contribution from this new vertical to be minimal in 2026, they anticipate a more meaningful impact beginning in 2027.
• Guidance (Management Expectations):
• Revenue: Management raised full-year 2026 revenue guidance to $798 million–$804 million (previously $732 million–$742 million).
• Profitability: Management raised full-year income from operations guidance to $205 million–$215 million, implying a 26% margin at the midpoint (previously 21% margin).
• Market Context: The company targets a large addressable market, noting that one in six American adults suffers from migraines, a demographic driving over $16,000 in annual healthcare spend on average.

4. Archetype and Conviction

• Archetype: Growth Leader.
• Fit: The company demonstrates classic growth leader characteristics: accelerating revenue (47% YoY), expanding billings (52% YoY), and rapidly improving margins (guidance raised to 26% operating margin). The 97% retention rate and expanding client base (2,849 clients) indicate strong product-market fit and pricing power.
• Valuation & Conviction Context:
• Thesis Strength: Moderate. The business fundamentals are robust, but the setup is tactical rather than driven by a new secular narrative.
• Evidence Quality: High. The evidence block is dense with primary financial data (earnings transcripts, SEC filings) confirming growth, margin expansion, and client acquisition.
• Rerating Potential: Significant. The shift from a growth story to a profitable growth story (26% operating margin guidance) combined with the expansion into in-person care (HingeSelect) provides a catalyst for multiple expansion if the breakout occurs.
• Conviction Stack: The setup is a partial signal (Forming Coil). The business fundamentals are strong (Growth Leader). The combination suggests a high-probability setup *if* the breakout fires, but the trade is not yet active.

5. Invalidations, Strengths, and Gaps

• Strengthening Factors: A confirmed breakout above the coil's upper resistance level, accompanied by volume, would confirm the setup. Continued adherence to the raised guidance and successful ramp-up of HingeSelect revenue in 2027 would further strengthen the long-term thesis.
• Gaps in Evidence:
• Cash Position: No specific cash balance or burn rate data is provided for Q1 2026, though the path to profitability is clear.
• HingeSelect Financials: While the launch is noted, specific revenue contribution figures for HingeSelect in 2026 are explicitly stated as "minimal," leaving a gap on the exact magnitude of this new revenue stream.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Q1 2026 revenue grew 47% YoY to $182M; 12-month billings up 52% to $770M; raised full-year operating margin guidance to 26%. Key risks: HingeSelect revenue contribution remains minimal in 2026 as expected; technical setup is forming but not yet confirmed (breakout not fired); high ATR (4.7%) implies elevated volatility risk. Sizing hint: Position size should be conservative until the breakout fires, as the setup is currently a partial signal. Expected path: Management expects HingeSelect to drive meaningful revenue starting in 2027; price likely consolidates in the forming coil before a potential expansion if guidance holds. Expected horizon: 3 to 6 months for the setup to resolve (breakout or invalidation).